---
company: Cosmos Health Inc.
ticker: COSM
form: 8-K
filed: 2026-08-20
accession: 0001477932-26-005195
source: https://www.sec.gov/Archives/edgar/data/1474167/000147793226005195/
---

# Cosmos Health (COSM) earnings release, August 20, 2026

Cosmos Health Inc. (COSM) · Form 8-K, Item 2.02 · Filed 2026-08-20 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1474167/000147793226005195/)

Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway

CHICAGO, IL / GLOBE NEWSWIRE / August 19, 2026 /

Cosmos Health Inc.

("Cosmos Health" or the "Company")

(NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the second quarter and six months ended June 30, 2026.

Second Quarter and First Half 2026 Financial Highlights

Income Statement

Cosmos Health delivered its highest second-quarter and first-half revenue in Company history, with growth contributed by every core division. Decahedron nearly doubled its revenue in the United Kingdom, Cana Laboratories built its contract manufacturing orderbook to an all-time high of over 25 million units, CosmoFarm added more than 75 new pharmacies to its distribution network, and the Company's proprietary brands — including Sky Premium Life, C-Sept and C-Scrub — continued their international expansion.

Balance Sheet

Cosmos Health strengthened its capital structure during the first half of 2026, reducing total liabilities for a second consecutive quarter while lifting stockholders' equity and improving working capital efficiency, with receivables and inventory both declining against nearly 30% revenue growth on improved collections and more disciplined inventory management.

Share Repurchase Program

On June 26, 2026, the Company's Board of Directors authorized a share repurchase program of up to $5.0 million, expiring December 31, 2026 and renewable at the Company's sole discretion. Cosmos Health repurchased 2,650,000 shares for approximately $513,000 during the second quarter, and open market purchases have continued into Q3 2026, bringing total repurchases as of this date to 5,112,000 shares for approximately $1.11 million.

Q2 2026 Business Highlights

Commercial Expansion

United States Expansion

Contract Manufacturing

Clinical Validation and New Categories

R&D and Innovation

Corporate and Capital Structure

Management Commentary

Greg Siokas, CEO of Cosmos Health, stated:

"Q2 2026 was a record second quarter, with revenue of $18.99 million, up 29% year-over-year, capping a record first half of $36.91 million. On an adjusted basis, this represents an annualized revenue run-rate in excess of $75 million — a new milestone for Cosmos, and one achieved before any impact from potential acquisitions or from second-half seasonality, which was materially stronger last year and which we expect again this year. Every core division contributed: CosmoFarm added over 75 pharmacies, Cana built its contract manufacturing orderbook to over 25 million units, and Decahedron nearly doubled its revenue in the United Kingdom.

Our proprietary brands continued to gain ground. Sky Premium Life extended its reach across Europe and the UAE through new distribution agreements. C-Scrub and C-Sept continued to build momentum, with C-Sept PRO gaining traction across leading Greek hospital groups, and C-Scrub cleared EN 12791 for surgical hand disinfection — opening the hospital and surgical channels as well as an entirely new vertical for us in animal health.

During the quarter we also took our U.S. expansion from concept to execution with the 18 Series, a portfolio we are building toward 18 clinically validated products spanning liver health, joint and inflammation support, cardiovascular health, men's wellness and healthy aging, among other areas. Supported by local manufacturing, we expect the United States to become one of our principal growth engines.

Equally important is how we achieved this growth. Adjusted gross profit rose 58% in the quarter with adjusted gross margin expanding 165 basis points, operating expenses grew at little more than half the rate of revenue, and we reduced both receivables and inventory while revenue grew nearly 30%. That is the operating leverage we have been building toward, and we are investing to extend it — a new capsule production line at Cana, robotic automation and AI systems at CosmoFarm, and AI integration across order management, warehousing and supply chain, where we see scope to reduce certain operating expenses further.

We also cut total liabilities by $6.3 million since year-end, lifting stockholders' equity 12% to $20.7 million and improving our liabilities-to-assets ratio by 550 basis points. Separately, we began buying back our own stock because we believe our shares trade well below the underlying value of our diversified asset base and growth prospects.

Moving forward, we are starting to see the benefits of economies of scale and vertical integration, and we expect increased efficiencies to play an important role as we progress toward sustained profitability. That momentum carries into Q3 2026 across every core segment, with our U.S. platform beginning to contribute."

## Financial statements

### Income Statement (Three Months Ended June 30, — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| GAAP FIGURES | REVENUE | 18,986,376 | 14,745,702 | 36,914,268 | 28,458,230 |
| GAAP FIGURES | GROSS PROFIT | 1,511,662 | 1,163,814 | 2,892,833 | 3,213,613 |
| GAAP FIGURES | TOTAL OPERATING EXPENSES | 4,437,269 | 3,809,133 | 8,002,619 | 6,692,077 |
| GAAP FIGURES | GAIN (LOSS) FROM OPERATIONS | -2,925,607 | -2,645,319 | -5,109,786 | -3,478,464 |
| GAAP FIGURES | TOTAL OTHER INCOME (EXPENSE), NET | -3,160,915 | -182,749 | -3,782,159 | -167,701 |
| GAAP FIGURES | NET LOSS | -6,086,522 | -2,828,068 | -8,891,945 | -3,646,165 |
| NON-GAAP FIGURES* | ADJUSTED REVENUE | 19,318,302 | 14,745,702 | 37,716,796 | 28,458,230 |
| NON-GAAP FIGURES* | ADJUSTED GROSS PROFIT | 1,843,588 | 1,163,814 | 3,695,361 | 3,213,613 |
| NON-GAAP FIGURES* | ADJUSTED EBITDA | -1,130,888 | -1,312,280 | -1,719,040 | -1,139,948 |
| NON-GAAP FIGURES* | ADJUSTED NET INCOME (LOSS) | -1,687,511 | -1,595,307 | -2,652,219 | -1,518,756 |

### Income Statement (Three Months Ended June 30,)

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| (in $) | REVENUE | 18,986,376 | 14,745,702 | 36,914,268 | 28,458,230 |
| (in $) | Sales discount reversal | 331,926 |  | 802,528 |  |
| (in $) | ADJUSTED REVENUE | 19,318,302 | 14,745,702 | 37,716,796 | 28,458,230 |
| (in $) | GROSS PROFIT | 1,511,662 | 1,163,814 | 2,892,833 | 3,213,613 |
| (in $) | Sales discount reversal | 331,926 |  | 802,528 |  |
| (in $) | ADJUSTED GROSS PROFIT | 1,843,588 | 1,163,814 | 3,695,361 | 3,213,613 |
| (in $) | INCOME (LOSS) BEFORE INCOME TAXES | -6,086,522 | -2,828,068 | -8,891,945 | -3,646,165 |
| Adjustments (add back): | Depreciation and amortization expense | 349,181 | 353,862 | 697,360 | 674,301 |
| Adjustments (add back): | Interest (income) / expense, net | 556,623 | 283,027 | 933,179 | 378,808 |
| Adjustments (add back): | EBITDA | -5,180,717 | -2,191,179 | -7,261,405 | -2,593,056 |
| Adjustments (add back): | Sales discount reversal | 331,926 |  | 802,528 |  |
| Adjustments (add back): | Non-recurring and extraordinary items | 554,753 | 376,157 | 796,215 | 504,584 |
| Adjustments (add back): | Stock based compensation | 558,858 | 603,020 | 1,094,644 | 1,159,632 |
| Adjustments (add back): | Other (income) / expense, net | -37,979 | 42,190 | -479,041 | 110,327 |
| Adjustments (add back): | (Gain) / loss on equity investments, net | -3,650 | -2,639 | 7,602 | -5,781 |
| Adjustments (add back): | Non-cash interest expense / Change in fair value of convertible notes | 2,785,787 | 302,695 | 2,936,657 | 302,695 |
| Adjustments (add back): | Change in fair value of derivative liability | -577,347 |  | -809,315 |  |
| Adjustments (add back): | Gain/(Loss) on digital assets | 404,145 |  | 846,584 |  |
| Adjustments (add back): | Foreign currency transaction, net | 33,336 | -442,524 | 346,493 | -618,348 |
| Adjustments (add back): | ADJUSTED EBITDA | -1,130,888 | -1,312,280 | -1,719,040 | -1,139,948 |
| Adjustments (add back): | Interest income / (expense), net | -556,623 | -283,027 | -933,179 | -378,808 |
| Adjustments (add back): | ADJUSTED NET INCOME | -1,687,511 | -1,595,307 | -2,652,219 | -1,518,756 |

### Balance Sheet (June 30, 2026 — CONDENSED CONSOLIDATED BALANCE SHEET DATA)

| | June 30, 2026 – (Unaudited) | March 31, 2026 – (Unaudited) | December 31, 2025 – (Audited) |
|---|---:|---:|---:|
| ASSETS | Cash & cash equivalents | 2,445,168 | 2,158,921 | 3,459,893 |
| ASSETS | Inventory | 4,518,560 | 5,650,458 | 5,778,142 |
| ASSETS | Accounts receivable, prepaid expenses and other current assets | 29,217,388 | 28,594,752 | 28,662,583 |
| ASSETS | Property and equipment, net | 10,140,150 | 10,280,203 | 10,578,858 |
| ASSETS | Goodwill and intangible assets, net | 6,965,934 | 7,225,011 | 7,569,695 |
| ASSETS | Loans receivable | 3,472,916 | 3,605,388 | 3,633,839 |
| ASSETS | Other noncurrent assets | 4,701,838 | 4,854,278 | 5,794,508 |
| ASSETS | TOTAL ASSETS | 61,461,954 | 62,369,011 | 65,477,518 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Accounts payable and accrued expenses | 15,297,625 | 15,689,061 | 17,412,973 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Other current liabilities | 6,760,621 | 6,701,051 | 6,047,940 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Lines of credit | 8,745,807 | 7,856,208 | 9,177,684 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Notes payable | 7,075,633 | 9,954,812 | 11,485,084 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Other non-current and finance/lease liabilities | 2,907,785 | 2,341,520 | 2,929,208 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Stockholders' and mezzanine equity | 20,674,483 | 19,826,359 | 18,424,629 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | TOTAL LIABILITIES AND STOCKHOLDERS'/MEZZANINE EQUITY | 61,461,954 | 62,369,011 | 65,477,518 |
